Evidence map›Paper›PMID 37441326›Full record

ArticleTherapeutic advances in medical oncology2023

Skeletal

Jorinde Janssen, Walter Noordzij, Ton Velleman, Igle Jan de Jong, Johannes A Langendijk, J Fred Verzijlbergen, Gilles N Stormezand, Shafak Aluwini

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. A prospective, exploratory study ofEuropean journal of nuclear medicine and molecular imaging · 2026
    Article
  2. Synthesizing [BMC cancer · 2025
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jorinde JanssenDepartment of Radiation Oncology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, Groningen 9713GZ, The Netherlands.ORCID https://orcid.org/0000-0002-1624-0186
Walter NoordzijDepartment of Radiology and Nuclear Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Ton VellemanDepartment of Radiology and Nuclear Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Igle Jan de JongDepartment of Urology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Johannes A LangendijkDepartment of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
J Fred VerzijlbergenDepartment of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Gilles N StormezandDepartment of Radiology and Nuclear Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Shafak AluwiniDepartment of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/objectives: Accurate and uniform interpretation and reporting of metastatic prostate cancer (PCa) lesions on prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) are indispensable. Design/methods: In total, 33 Results: Observers qualified most lesions as not malignant (81-91%) and the overall mean interobserver agreement was moderate on both patient (κ: 0.54) and lesion level (κ: 0.55). In 52 lesions without corresponding CT substrate, the rating resulted in not malignant in 95-100%. Availability of additional imaging (60% of lesions) did not improve interobserver agreement (κ: 0.39 on lesion level) and resulted in unchanged rating for all observers in 78%. Conclusion: This interobserver analysis of skeletal

Indexed as

18F-PSMA-1007interobserver agreementprostate cancerPSMA PET/CTskeletal uptake

Identifiers

PMID37441326
PMCPMC10333984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.